Propelling Glioblastoma Research: Aragen Bioscience's Orthotopic Model Solutions

Glioblastoma multiforme (GBM) is an aggressive and treatment-resistant brain cancer that poses significant challenges in oncology due to its rapid proliferation, infiltration, and inherent resistance to most conventional therapies. To advance research in this area, the orthotopic brain tumor model offers a more accurate and reliable representation of human physiology than traditional models, making it an indispensable tool for studying the disease, testing potential treatments, and investigating drug delivery mechanisms.

In this study, we developed a luciferase-based orthotopic GBM model by intracranial injection of the luciferase-tagged U-87 MG human glioblastoma cell line into athymic nude mice. This model allows for precise and continuous monitoring of tumor growth and therapeutic response through non-invasive bioluminescence imaging (BLI), which is essential for assessing the efficacy of anti-GBM therapeutics. The ability to track tumor progression and therapy outcomes in real-time provides valuable insights into the preclinical development of new treatments, acting as a critical step before moving into clinical trials and patient studies.